Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 11, 2006. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure regarding equity plan transactions rather than a financial results report.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details an increase in notional interests in Ordinary Shares and American Depositary Receipts (ADRs) for specific executives following the notional re-investment of dividends paid on July 6, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It strictly reports on the mechanics of the Performance Share Plan dividend re-investment.
Important Facts for Investors
- Transaction Type: Notification of increased notional interests in shares/ADRs for directors and managers via dividend re-investment.
- Valuation: Transactions occurred at a price of GBP 15.40 per Ordinary Share and $57.17 per ADR.
- Participants: Includes Dr. JP Garnier, Mr. J Heslop, Dr. M Slaoui, Mr. R Bondy, Dr. F Calhoun, Mr. J Clarke, Mr. M Dunoyer, Dr. R Greig, Mr. D Learmouth, Mr. D Phelan, Dr. D Pulman, Mr. D Stout, Mr. C Viehbacher, and Mr. A Witty.
- Payout Terms: Notional dividends will be paid out based on the percentage of holdings that vest after the relevant three-year measurement period.
- Regulatory Basis: Filed in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).